Log in to save to my catalogue

Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction...

Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8358015

Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders

About this item

Full title

Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders

Publisher

England: Nature Publishing Group

Journal title

Neuropsychopharmacology (New York, N.Y.), 2021-09, Vol.46 (10), p.1802-1810

Language

English

Formats

Publication information

Publisher

England: Nature Publishing Group

More information

Scope and Contents

Contents

Identifying genetic contributors to cognitive impairments in psychosis-spectrum disorders can advance understanding of disease pathophysiology. Although CNS medications are known to affect cognitive performance, they are often not accounted for in genetic association studies. In this study, we performed a genome-wide association study (GWAS) of glo...

Alternative Titles

Full title

Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8358015

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8358015

Other Identifiers

ISSN

0893-133X

E-ISSN

1740-634X

DOI

10.1038/s41386-021-01057-8

How to access this item